{"id":59701,"date":"2022-12-13T14:42:04","date_gmt":"2022-12-13T14:42:04","guid":{"rendered":"https:\/\/elpais.com\/ciencia\/2022-12-13\/moderna-y-merck-anuncian-resultados-prometedores-en-los-ensayos-de-su-vacuna-contra-el-melanoma.html"},"modified":"2022-12-13T14:42:04","modified_gmt":"2022-12-13T14:42:04","slug":"moderna-y-merck-anuncian-resultados-prometedores-en-los-ensayos-de-su-vacuna-contra-el-melanoma","status":"publish","type":"post","link":"https:\/\/forocilac.org\/en\/moderna-y-merck-anuncian-resultados-prometedores-en-los-ensayos-de-su-vacuna-contra-el-melanoma\/","title":{"rendered":"Moderna and Merck announce promising results in trials of their melanoma vaccine"},"content":{"rendered":"<p>Moderna y Merck han anunciado este martes resultados prometedores en sus ensayos preliminares (fase 2b) de su terapia contra el c\u00e1ncer de piel. El uso de una vacuna de Moderna con ARN mensajero (el m\u00e9todo que se utiliz\u00f3 para desarrollar a toda velocidad vacunas contra el coronavirus) combinado con el f\u00e1rmaco Keytrude de Merck ofrece mejores resultados que la administraci\u00f3n en solitario del medicamento, seg\u00fan han comunicado ambas compa\u00f1\u00edas. Seg\u00fan afirman las empresas, el riesgo de recurrencia o muerte se reduce un 44%.<\/p>\n<p><a href=\"https:\/\/elpais.com\/ciencia\/2022-12-13\/moderna-y-merck-anuncian-resultados-prometedores-en-los-ensayos-de-su-vacuna-contra-el-melanoma.html\" >Keep reading<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Tests of skin cancer therapy with the messenger RNA method, successfully tested with covid, are still in a preliminary phase<\/p>","protected":false},"author":1650,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[123],"tags":[],"class_list":{"0":"post-59701","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-portal"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/users\/1650"}],"replies":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/comments?post=59701"}],"version-history":[{"count":1,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59701\/revisions"}],"predecessor-version":[{"id":59702,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59701\/revisions\/59702"}],"wp:attachment":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/media?parent=59701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/categories?post=59701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/tags?post=59701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}